Les scientifiques ont découvert qu’un médicament d’#Immunothérapie contre le #Cancer approuvé par la #FDA le " #Nivolumab / #Relatlimab" bloque la progression de la maladie de #Parkinson en empêchant la propagation de protéines cérébrales toxiques qui causent des lésions neuronales

Daniel Flora: A Paradigm Shift in Cancer Care - Immunotherapy Before Surgery Delivers Long-Term Survival - OncoDaily Daniel Flora: A Paradigm Shift in Cancer Care - Immunotherapy Before Surgery Delivers Long-Term Survival / Alexander Lazar, cancer, Daniel Flora, Denái R.

A Paradigm Shift in Cancer Care: Immunotherapy Before Surgery Delivers Long-Term Survival - Daniel Flora
@dbfloramd.bsky.social

oncodaily.com/insight/immu...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Immunotherapy #Relatlimab #Nivolumab #Melanoma

Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.

Nivolumab + relatlimab show promising intracranial activity in melanoma brain metastases! A beacon of hope for resistant cases and a call for more research!
#Melanoma #BrainMetastases #Immunotherapy #Nivolumab #Relatlimab #CheckpointInhibitors #TCSC #Oncology

www.cancernetwork.com/view/nivolum...

Hidehito Horinouchi Shared ASCO 2025 Abstract on Relatlimab Biology in Metastatic NSCLC - OncoDaily Hidehito Horinouchi Shared ASCO 2025 Abstract on Relatlimab Biology in Metastatic NSCLC / ASCO 2025, cancer, Hidehito Horinouchi, Lung cancer, NSCLC,

Hidehito Horinouchi Shares ASCO 2025 Abstract on Relatlimab Biology in Metastatic NSCLC
@hhorinouchi.bsky.social
@ascocancer.bsky.social

oncodaily.com/blog/asco-20...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO2025 #Relatlimab #NSCLC #LungCancer